Stereotactic Radiation Shows Ability to Significantly Extend Survival in Cancer Patients with Multiple Metastasis

Stereotactic Radiation Shows Ability to Significantly Extend Survival in Cancer Patients with Multiple Metastasis
Patients whose cancer returns at multiple sites after treatment — called oligometastatic cancer — are generally thought incurable, but a recent Phase 2 trial found that a highly precise form of radiation can significantly extend these patients' lives if the spread shows small tumors, without diminishing life quality. The approach was tested in patients with up to five metastatic sites, and doubled the time a patient lived without disease progression. The findings will be presented next week at the American Society for Radiation Oncology (ASTRO) 2018 Annual Meeting. David Palma, MD, PhD, a researcher at Lawson Health Research Institute – the research institute of London Health Scie
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *